Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena

被引:8
作者
Samaddar, Arghadip [1 ]
Grover, Malika [1 ]
Nag, Vijaya Lakshmi [1 ]
机构
[1] All India Inst Med Sci, Dept Microbiol, Jodhpur, Rajasthan, India
关键词
coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; antiviral; anti-inflammatory; drug repurposing; pathophysiology; immunotherapy; CONVALESCENT PLASMA THERAPY; CORONAVIRUS DISEASE 2019; NUCLEOCAPSID PROTEINS; SARS; INFECTION; REPLICATION; SARS-COV-2; MODEL; INHIBITOR; MORTALITY;
D O I
10.3389/fphar.2020.585888
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Coronavirus disease 2019 (COVID-19), an acute onset pneumonia caused by a novelBetacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the Wuhan City of China in December 2019 and evolved into a global pandemic. To date, there are no proven drugs or vaccines against this virus. Hence, the situation demands an urgent need to explore all potential therapeutic strategies that can be made available to prevent the disease progression and improve patient outcomes. In absence of clinically proven treatment guidelines, several repurposed drugs and investigational agents are currently being evaluated in clinical trials for their probable benefits in the treatment of COVID-19. These include antivirals (remdesivir, lopinavir/ritonavir, umifenovir, and favipiravir), interferon, antimalarials (chloroquine/hydroxychloroquine), antiparasitic drugs (ivermectin and nitazoxanide), biologics (monoclonal antibodies and interleukin receptor antagonist), cellular therapies (mesenchymal stem cells and natural killer cells), convalescent plasma, and cytokine adsorber. Though several observational studies have claimed many of these agents to be effective based on theirin vitroactivities and extrapolated evidence from SARS and Middle East respiratory syndrome (MERS) epidemics, the currently available data remains inconclusive because of ill-defined patient selection criteria, small sample size, lack of concurrent controls, and use of intermediary outcomes instead of patient-relevant outcomes. Moreover, there is a need to clearly define the patient populations who warrant therapy and also the timing of initiation of treatment. Understanding the disease pathology responsible for the clinical manifestations of COVID-19 is imperative to identify the potential targets for drug development. This review explains the pathophysiology of COVID-19 and summarizes the potential treatment candidates, which can provide guidance in developing effective therapeutic strategies.
引用
收藏
页数:19
相关论文
共 110 条
  • [51] Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
    Kadam, Rameshwar U.
    Wilson, Ian A.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (02) : 206 - 214
  • [52] Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response
    Kindler, E.
    Thiel, V.
    Weber, F.
    [J]. ADVANCES IN VIRUS RESEARCH, VOL 96: CORONAVIRUSES, 2016, 96 : 219 - 243
  • [53] Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience
    Ko, Jae-Hoon
    Seok, Hyeri
    Cho, Sun Young
    Ha, Young Eun
    Baek, Jin Yang
    Kim, So Hyun
    Kim, Yae-Jean
    Park, Jin Kyeong
    Chung, Chi Ryang
    Kang, Eun-Suk
    Cho, Duck
    Mueller, Marcel A.
    Drosten, Christian
    Kang, Cheol-In
    Chung, Doo Ryeon
    Song, Jae-Hoon
    Peck, Kyong Ran
    [J]. ANTIVIRAL THERAPY, 2018, 23 (07) : 617 - 622
  • [54] Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists
    Kopecky-Bromberg, Sarah A.
    Martinez-Sobrido, Luis
    Frieman, Matthew
    Baric, Ralph A.
    Palese, Peter
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (02) : 548 - 557
  • [55] Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
    Leng, Zikuan
    Zhu, Rongjia
    Hou, Wei
    Feng, Yingmei
    Yang, Yanlei
    Han, Qin
    Shan, Guangliang
    Meng, Fanyan
    Du, Dongshu
    Wang, Shihua
    Fan, Junfen
    Wang, Wenjing
    Deng, Luchan
    Shi, Hongbo
    Li, Hongjun
    Hu, Zhongjie
    Zhang, Fengchun
    Gao, Jinming
    Liu, Hongjian
    Li, Xiaoxia
    Zhao, Yangyang
    Yin, Kan
    He, Xijing
    Gao, Zhengchao
    Wang, Yibin
    Yang, Bo
    Jin, Ronghua
    Stambler, Ilia
    Lim, Lee Wei
    Su, Huanxing
    Moskalev, Alexey
    Cano, Antonio
    Chakrabarti, Sasanka
    Min, Kyung-Jin
    Ellison-Hughes, Georgina
    Caruso, Calogero
    Jin, Kunlin
    Zhao, Robert Chunhua
    [J]. AGING AND DISEASE, 2020, 11 (02): : 216 - 228
  • [56] Levitzky M G, 1984, Physiologist, V27, P102
  • [57] Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury
    Li, Dong
    Liu, Qingshen
    Qi, Lei
    Dai, Xiaoyu
    Liu, Huan
    Wang, Yunshan
    [J]. MOLECULAR MEDICINE REPORTS, 2016, 14 (02) : 1681 - 1692
  • [58] Coronavirus infections and immune responses
    Li, Geng
    Fan, Yaohua
    Lai, Yanni
    Han, Tiantian
    Li, Zonghui
    Zhou, Peiwen
    Pan, Pan
    Wang, Wenbiao
    Hu, Dingwen
    Liu, Xiaohong
    Zhang, Qiwei
    Wu, Jianguo
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (04) : 424 - 432
  • [59] Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
    Lian, N.
    Xie, H.
    Lin, S.
    Huang, J.
    Zhao, J.
    Lin, Q.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (07) : 917 - 921
  • [60] Long Q.X., 2020, NAT MED, V26, P845, DOI DOI 10.1038/s41591-020-0897-1